Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Steris (STE) Surpasses Q2 Earnings Estimates
Steris (STE) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to earnings of $2.03 per share a year ago.
Steris beats quarterly estimates on continued demand for medical procedures
Medical equipment maker Steris beat second-quarter profit estimates on Wednesday, on continued demand for non-urgent medical procedures that boosted sales of its surgical and examination tools.
Steris (STE) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Beyond analysts' top -and-bottom-line estimates for Steris (STE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STE Gears Up for Q2 Earnings: Here's What You Need to Know
STERIS' second-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog.
Steris (STE) Up 3% Since Last Earnings Report: Can It Continue?
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Reasons to Retain STERIS Stock in Your Portfolio for Now
STE's strong prospects in the healthcare business arm bode well for investors.
Steris: Q2 Numbers Solidify Buy Thesis
STE's Q1 FY'25 numbers were in line with expectations, with upsides in the healthcare and AST divisions. The company shows consistent free cash flow production and stable earnings on its capital base. I've revised our estimate on the intrinsic worth of the business to $270 per share, reiterating a buy.
Don't Overlook Steris (STE) International Revenue Trends While Assessing the Stock
Review Steris' (STE) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls
STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.
STERIS plc (STE) Q1 2025 Earnings Call Transcript
STERIS plc (NYSE:STE ) Q1 2025 Earnings Conference Call August 7, 2024 9:00 AM ET Company Participants Julie Winter - Investor Relations Mike Tokich - Senior Vice President & Chief Financial Officer Dan Carestio - President & Chief Executive Officer Conference Call Participants Brett Fishbin - KeyBanc Mike Matson - Needham & Company Michael Polark - Wolfe Research Jason Bednar - Piper Sandler Dave Turkaly - JMP Securities Operator Good morning, and welcome to the STERIS First Quarter of 2025 Earnings Call. [Operator Instructions] Also please be aware that today's call is being recorded.
